EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Prostate Cancer Awareness Month: Prostate cancer screening in 2026ByShiv B. Patel, MD,Hannah ClarkeSeptember 3rd 2026
Enrollment goal met in phase 3 study of 68Ga-PSMA-PET in pre-biopsy settingByHannah ClarkeSeptember 2nd 2026
Cardiovascular referral improves risk-factor control in prostate cancer, but not clinical eventsByHannah ClarkeSeptember 2nd 2026
Martin Schoen, MD, PhD, on selecting among ARPIs in prostate cancerByMartin Schoen, MD, PhDSeptember 1st 2026